Diagnosis and management of intestinal Behçet's diseas

Tadakazu Hisamatsu, Makoto Naganuma, Katsuyoshi Matsuoka, Takanori Kanai

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Behçets disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalClinical Journal of Gastroenterology
Volume7
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Intestinal Diseases
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Aphthous Stomatitis
Japan
Chronic Disease
Hemorrhage
Skin
Therapeutics

Keywords

  • Adalimumab
  • Anti-TNFα mAb
  • Intestinal Behçets disease
  • Trisomy 8

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Diagnosis and management of intestinal Behçet's diseas. / Hisamatsu, Tadakazu; Naganuma, Makoto; Matsuoka, Katsuyoshi; Kanai, Takanori.

In: Clinical Journal of Gastroenterology, Vol. 7, No. 3, 2014, p. 205-212.

Research output: Contribution to journalArticle

Hisamatsu, Tadakazu ; Naganuma, Makoto ; Matsuoka, Katsuyoshi ; Kanai, Takanori. / Diagnosis and management of intestinal Behçet's diseas. In: Clinical Journal of Gastroenterology. 2014 ; Vol. 7, No. 3. pp. 205-212.
@article{1f7e2df4cb3c4553b28661c5a2cd8c99,
title = "Diagnosis and management of intestinal Beh{\cc}et's diseas",
abstract = "Beh{\cc}ets disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.",
keywords = "Adalimumab, Anti-TNFα mAb, Intestinal Beh{\cc}ets disease, Trisomy 8",
author = "Tadakazu Hisamatsu and Makoto Naganuma and Katsuyoshi Matsuoka and Takanori Kanai",
year = "2014",
doi = "10.1007/s12328-014-0488-0",
language = "English",
volume = "7",
pages = "205--212",
journal = "Clinical Journal of Gastroenterology",
issn = "1865-7257",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Diagnosis and management of intestinal Behçet's diseas

AU - Hisamatsu, Tadakazu

AU - Naganuma, Makoto

AU - Matsuoka, Katsuyoshi

AU - Kanai, Takanori

PY - 2014

Y1 - 2014

N2 - Behçets disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.

AB - Behçets disease (BD) is a chronic relapsing disease with multiple organ system involvement characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. Little clinical evidence is available regarding the management of patients with intestinal BD, despite recognition that the presence of intestinal lesions is a poor prognostic factor, causing perforation and massive bleeding. Many recent case reports have suggested that anti-tumor necrosis factor alpha (TNF)α monoclonal antibodies (mAbs) are effective in patients with intestinal BD. Adalimumab, a fully human anti-TNFα mAb, has been approved in Japan for the treatment of intestinal BD. Here, we review the pathogenesis, diagnosis and management of intestinal BD, including evidence of the efficacy of anti-TNFα mAbs.

KW - Adalimumab

KW - Anti-TNFα mAb

KW - Intestinal Behçets disease

KW - Trisomy 8

UR - http://www.scopus.com/inward/record.url?scp=84903700105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903700105&partnerID=8YFLogxK

U2 - 10.1007/s12328-014-0488-0

DO - 10.1007/s12328-014-0488-0

M3 - Article

C2 - 24883128

AN - SCOPUS:84903700105

VL - 7

SP - 205

EP - 212

JO - Clinical Journal of Gastroenterology

JF - Clinical Journal of Gastroenterology

SN - 1865-7257

IS - 3

ER -